Lombardia
我们是谁
Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
肿瘤诊断精准免疫肿瘤学和体细胞靶向合理性(TAPISTRY)平台研究
BMS-986288单独或与Nivolumab联合治疗晚期实体瘤的免疫疗法研究